Is Loading NSTEMI with DAPT Convenient?

Pretreating non-ST elevation acute myocardial infarction (NSTEMI) patients with P2Y12 receptor inhibitors is not associated with improved clinical outcomes as it is to increased bleeding.

doble antiagregación los SCA sin ST

NSTEMI patients are often treated with platelet antiaggregants in the daily clinical practice despite the lack of evidence for its benefits.

This Swedish registry prospectively included 64857 patients undergoing NSTEMI receiving coronary angiography plus angioplasty between 2010 and 2018.

Propensity score matching was used to match patient cohorts between patients pretreated with P2Y12 inhibitors and those who did not.

92.4% of this large cohort of patients received one P2Y12 receptor antagonist, including clopidogrel (43.7%), ticagrelor (54.5%) and prasugrel (1.8%).


Read also: FFR and iFR Discordance in up to 20% of Cases: Which One Should Inform Our Decisions?


Pretreatment was not associated to benefits in terms of 30-day mortality (OR: 1.17; CI 95%, 0.66 to 2.11; p=0.58), mortality at one year (OR: 1.34; CI 95%, 0.77 to 2.34; p=0.30) or stent thrombosis (OR: 0.81; CI 95%, 0.42 to 1.55; p=0.52).

Pretreatment did produce increased in-hospital bleeding in nearly 50% of patients (OR: 1.49; CI 95%, 1.06 to 2.12; p=0.02).

Conclusion

Pretreatment with P2Y12 Receptor Antagonists Preceding Percutaneous Coronary Intervention in Non–ST-Segment Elevation Acute Coronary Syndromes does not bring clinical benefits and increases bleeding. This study strongly recommends against routine pretreatment of these group of patients with P2Y12 receptor antagonists before knowing their anatomy.

dworeck-2020-oi-200664-1600876647-78636-free

Original Title: Association of Pretreatment With P2Y12 Receptor Antagonists Preceding Percutaneous Coronary Intervention in Non–ST-Segment Elevation Acute Coronary Syndromes With Outcomes.

Reference: Christian Dworeck et al. JAMA Network Open. 2020;3(10):e2018735. doi:10.1001/jamanetworkopen.2020.18735.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....